Exciting progress was made in the more recentdevelopment of these cancer immunotherapies by combination of immunecheckpoint inhibitors and A2AR antagonists developed towithstand high adenosine concentrations, such as etrumadenant andinupadenant (Figure 1).10 This evidence concerns the gene ADORA2A and cancer.